Which medication has been shown to potentially increase walking speed in multiple sclerosis patients?

Dalfampridine is a medication specifically indicated for improving walking speed in patients with multiple sclerosis (MS). Its mechanism of action involves blocking potassium channels, which enhances action potential conduction in demyelinated fibers. This improved conduction can lead to better motor function, facilitating an increase in walking speed.

Research studies have demonstrated that Dalfampridine can significantly improve walking ability, as measured by the Timed 25-Foot Walk test. This evidence supports its role in addressing one of the common symptoms of MS—gait impairment—which can greatly affect the quality of life of patients.

In contrast, while Amantadine is sometimes used off-label for managing fatigue in MS patients, it does not have specific evidence supporting its effect on walking speed. Baclofen, on the other hand, is mainly prescribed for spasticity management and does not improve walking speed. The term "Modifier" does not refer to any specific medication but may imply therapies that modify the course of MS; however, these do not typically target improvements in walking speed directly. Thus, Dalfampridine stands out as the agent with supportive evidence for enhancing walking speed in individuals with MS.